MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Actinium Pharmaceuticals ROCE Ratio 2011-2026 | ATNM
Annual ROCE Ratio Actinium Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -128.58 | -142.72 | -51.3 | -33.94 | -36.05 | -348.86 | -269.96 | -196.84 | -149.08 | -113.0 | 1169.32 | 422.42 | -693.7 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1169.32 | -693.7 | -44.02 |
Quarterly ROCE Ratio Actinium Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -178.49 | -170.18 | -159.04 | -83.19 | -116.12 | -116.07 | -117.21 | -82.65 | -96.4 | -77.22 | -57.79 | -31.29 | -39.35 | -33.66 | -29.92 | -21.96 | -31.11 | -32.21 | -33.5 | -26.02 | -143.88 | -252.59 | -335.1 | -308.95 | -379.27 | -331.73 | -297.36 | -198.16 | -247.14 | -225.79 | -222.73 | -158.76 | -198.19 | -188.65 | -174.37 | -111.17 | -132.29 | -113.97 | -109.26 | -90.61 | 275.83 | 663.39 | 927.23 | 811.84 | 915.01 | 651.74 | 516.22 | 327.5 | 118.06 | -194.55 | -362.43 | -370.46 | -370.73 | -158.4 | -77.98 | -0.27 | 2.88 | 7.16 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 927.23 | -379.27 | -35.71 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 3.52 | -1.26 % | $ 1.05 B |  Canada |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
-27.26 | $ 3.26 | 3.99 % | $ 229 M |  Schweiz |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-180.78 | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-119.71 | - | 10.36 % | $ 9.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-48.11 | $ 4.13 | -1.67 % | $ 105 M | Schweiz |
 |
Arcturus Therapeutics Holdings
ARCT
|
-35.64 | $ 6.39 | -3.62 % | $ 175 M |  Israel |
 |
argenx SE
ARGX
|
-211.69 | $ 705.24 | 0.28 % | $ 25 B |  Niderland |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.45 | -4.43 % | $ 8.3 B |  Australia |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 229.27 | -0.76 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-65.67 | $ 6.07 | 0.33 % | $ 495 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-531.85 | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-57.76 | - | 4.14 % | $ 49.1 M | USA |
 |
BioCardia
BCDA
|
726.39 | $ 1.29 | 1.57 % | $ 27.3 M | USA |
 |
Anika Therapeutics
ANIK
|
-41.29 | $ 14.45 | 0.63 % | $ 212 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
AVEO Pharmaceuticals
AVEO
|
-108.03 | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.59 | -2.08 % | $ 16.3 M | USA |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.2 | $ 1.5 | -0.99 % | $ 383 M | Britain |
 |
Athira Pharma
ATHA
|
-225.02 | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 94.98 | 4.9 % | $ 27.2 B | Germany |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
14.24 | $ 8.31 | 3.04 % | $ 1.34 B | Britain |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | Britain |